Company intelligence / Profile preview
Acquist Therapeutics
San Francisco, California, USAacquist.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Acquist Therapeutics was a biopharmaceutical company focused on developing novel treatments for gout and chronic hyperuricemia. The company's primary focus was on URAT1 inhibitors, specifically developing prodrugs of potent uricosuric agents to improve safety and efficacy profiles. Its lead candidate, ACQT-1102, was designed to lower serum uric acid levels by inhibiting the reabsorption of uric acid in the kidneys. Acquist was acquired by Horizon Pharma in 2017 to bolster Horizon's gout franchise alongside Krystexxa. The company's technology originated from research conducted at the University of California, San Diego.
- Therapeutic areas
- RheumatologyMetabolic Disorders
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Acquist Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Acquist Therapeutics.